home / stock / onct / onct articles
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,5...
Oncternal Therapeutics Inc (NASDAQ: ONCT) updated the status of a recent study involving a treatment for relapsed or refractory aggressive B-c...
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Tuesday. Following the market opening Tuesday, the ...
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on t...
HC Wainwright has upgraded Oncternal Therapeutics Inc (NASDAQ: ONCT) to Buy from Neutral with a price target of $2. At the European ...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer ...